These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19740393)

  • 1. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
    Egorin MJ; Shah DD; Christner SM; Yerk MA; Komazec KA; Appleman LR; Redner RL; Miller BM; Beumer JH
    Br J Clin Pharmacol; 2009 Sep; 68(3):370-4. PubMed ID: 19740393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
    Tawbi H; Christner SM; Lin Y; Johnson M; Mowrey ET; Cherrin C; Chu E; Lee JJ; Puhalla S; Stoller R; Appleman LR; Miller BM; Beumer JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):207-11. PubMed ID: 24170263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antacid on imatinib absorption.
    Sparano BA; Egorin MJ; Parise RA; Walters J; Komazec KA; Redner RL; Beumer JH
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):525-8. PubMed ID: 18500518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
    Tawbi HA; Tran AL; Christner SM; Lin Y; Johnson M; Mowrey E; Appleman LR; Stoller R; Miller BM; Egorin MJ; Beumer JH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1143-7. PubMed ID: 24036846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
    Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
    Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
    Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
    J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
    Ishizuka M; Nagai S; Sakamoto KQ; Fujita S
    Xenobiotica; 2007 May; 37(5):503-13. PubMed ID: 17523053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence of a single 400-mg dose of imatinib 100-mg oral tablets and a 400-mg tablet in healthy adult Korean volunteers.
    Lee HW; Seong SJ; Park SM; Lee J; Gwon MR; Kim HJ; Lim SM; Lim MS; Kim W; Yang DH; Yoon YR
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):480-7. PubMed ID: 25881751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Omeprazole on the Pharmacokinetics of Rosuvastatin in Healthy Male Volunteers.
    Shah Y; Iqbal Z; Ahmad L; Khuda F; Khan A; Khan A; Khan MI; Ismail
    Am J Ther; 2016; 23(6):e1514-e1523. PubMed ID: 25719441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
    Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
    Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
    Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S
    Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.